Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection.
J Chemother
; 33(3): 193-197, 2021 May.
Article
in English
| MEDLINE | ID: covidwho-595918
ABSTRACT
Corona Virus Disease (CoVID-19) is an emerging public health problem rapidly spread globally. New treatment options for patients with severe symptoms and ways of reducing transmission in the community are taken into consideration. A retrospective study was conducted in the Department of Infectious Diseases of Alexandroupolis (Greece) including 16 patients with CoVID-19. They were classified into two groups, A and B. Group A received lopinavir/ritonavir as a third agent in the antiviral regimen, while group B did not. Lymphocytes were more significantly increased in patients of group A. Ferritin serum levels were also decreased significantly in these patients. Number of days needed for a first negative result of Real Time- Polymerase Chain Reaction (RT-PCR) was lower for Group A. The present study suggests that lopinavir/ritonavir may reduce the viral carriage in a shorter period of time compared with other antiviral regimens. Further studies are needed in order to evaluate the effectiveness of lopinavir/ritonavir in the treatment of patients with SARS-CoV-2 infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Ritonavir
/
Lopinavir
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Observational study
/
Randomized controlled trials
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
J Chemother
Journal subject:
Antineoplastic agents
/
Drug Therapy
Year:
2021
Document Type:
Article
Affiliation country:
1120009x.2020.1775424
Similar
MEDLINE
...
LILACS
LIS